Alvaro Pascual-Leone, MD, PhD


Changes in Vocation as Early Signs for Alzheimer Disease, Cognitive Issues: Alvaro Pascual-Leone, MD, PhD

The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]

Elia Pestana-Knight, MD


Ganaxolone’s Significant Effect on CDKL5 Deficiency Disorder: Elia Pestana-Knight, MD

The pediatric epileptologist at Cleveland Clinic provided insight on her presentation at the 2022 AAN Annual Meeting that evaluated ganaxolone in phase 3 study of patients with CDKL5 deficiency disorder. [WATCH TIME: 4 minutes]

Benzi Kluger, MD, MS


Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MS

The president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]

Ehud Marom


Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom

The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]

Ashley Asti


Not Your Grandmother’s Dopamine: PMD Alliance Releases On-Demand CME Topics in Advanced Therapeutics in Movement-Related Disorders

The PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.

Killian Meara


FDA to Add Warning Related to Guillain-Barré Syndrome on Johnson & Johnson Vaccine

Since vaccine administration, the CDC has announced 100 preliminary cases of Guillain-Barré syndrome.

Neepa J. Patel, MD


A Team Approach to Asleep Deep Brain Stimulation

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

Rodrigo de Holanda Mendonça, MD


Key Considerations in Treatment of Spinal Muscular Atrophy / Considerações essenciais para o tratamento da atrofia muscular espinhal

The expert panel shares clinical pearls for treatment and management of Spinal Muscular Atrophy. O painel de especialistas compartilha recomendações valiosas para o tratamento e manejo da atrofia muscular espinhal.

Pierre Tariot, MD


Aducanumab’s Implications for Future Clinical Trials: Pierre N. Tariot, MD

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

Hermona Soreq, PhD


Trial-and-Error Approach With Aducanumab: Hermona Soreq, PhD

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.

Ihtsham ul Haq, MD, FAAN


Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

Jonathan Graff-Radford, MD


Jonathan Graff-Radford, MD: Blood Tests as a Diagnostic Innovation in Alzheimer Disease

The neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.

Spencer Hutto, MD


CNS Demyelination and Autoimmune Neurology: Spencer Hutto, MD

The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.

Elias Kouchakji, MD


Elias Kouchakji, MD: Investigating Pamrevlumab for DMD in Phase 3 LELANTOS Study

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.

Vincent Martin, MD


Weighing Approaches on Preventive Use, Medication Overuse in Chronic Migraine: Vincent Martin, MD

The president of the National Headache Foundation discussed whether switching or continuing preventive medications has a benefit in patients who have chronic migraine with medication overuse. [WATCH TIME: 4 minutes]

Alexander Merkler, MD, MS


Future Research Regarding Anticoagulant Use in Reducing Recurrent Stroke: Alexander Merkler, MD, MS

The assistant professor of neurology at Weill Cornell Medicine discussed his future aspirations to uncover more about the beneficial effects of anticoagulants in reducing recurrent stroke. [WATCH TIME: 3 minutes]

Amynah Pradhan, PhD


Neuronal Complexity in a Model of Migraine: Amynah Pradhan, PhD

The associate professor of psychiatry at the University of Illinois at Chicago shared the findings of her and colleagues’ work that suggest that distinct cytoarchitectural changes occur in the brain that may underlie migraine chronification. [WATCH TIME: 4 minutes]

Jason Sico, MD, MHS


AUPN 2022 Veterans Health Administration Workshop

Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]

Ali Rezai, MD


Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD

The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]

Bryan Roth, MD, PhD


Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]

AJ Joshi, MD


Next Steps for ATA188, Research Related to EBV and Multiple Sclerosis: AJ Joshi, MD

The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]

Rebecca Erwin Wells, MD, MPH


The Changing Landscape of Preventative Migraine Treatments

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.

Douglas J. Gelb, MD, PhD


AUPN Leadership Minute Episode 9: Engaging Medical Students in Neurology – Part 2

Episode 9 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the Veterans Health Administration; and Douglas J. Gelb, MD, PhD, of the University of Michigan [WATCH TIME: 5 minutes]

Rana K. Zabad, MD, FAAN


The Evolving Diagnostic Criteria for Multiple Sclerosis

Join Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.

Ifrah Zawar, MD


Worse Clinical Outcomes, Higher Mortality Rates, and Shorter Lifespans in Epilepsy and Dementia: Ifrah Zawar, MD

The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]

Sana Somani, MD, MBBS


Preventing Secondary Stroke: Practical Application of Updated Guidelines

Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.

Diana Castro, MD


Advice to Community Neurologists Treating SMA

Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).

Tyler Kaplan, MD


Bruton Tyrosine Kinase Inhibitors: A New Hope for the Management of Progression in MS?

Several therapies are progressing through the development pipeline and have shown promising data, setting up the multiple sclerosis treatment toolbox for possible expansion in coming years.

Zubair Ahmed, MD


Characterizing Real-World Outcomes With Eptinezumab in Migraine: Zubair Ahmed, MD

The neurologist from Cleveland Clinic discussed the importance of studying real-world outcomes in patients with migraine using CGRPs such as eptinezumab.

© 2023 MJH Life Sciences

All rights reserved.